AEON Biopharma, Inc. (AEON)
| Market Cap | 19.74M +249.1% |
| Revenue (ttm) | n/a |
| Net Income | -60.11M |
| EPS | -3.15 |
| Shares Out | 26.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,804 |
| Open | 0.7300 |
| Previous Close | 0.7500 |
| Day's Range | 0.7300 - 0.7870 |
| 52-Week Range | 0.5300 - 1.4500 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 6.70 (+793.1%) |
| Earnings Date | May 14, 2026 |
About AEON
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AEON stock is "Strong Buy." The 12-month stock price target is $6.7, which is an increase of 793.10% from the latest price.
News
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewo...
AEON Biopharma Earnings release: Q1 2026
AEON Biopharma released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
AEON Biopharma Quarterly report: Q1 2026
AEON Biopharma has published its Q1 2026 quarterly earnings report on May 14, 2026.
Aeon Biopharma management to meet virtually with Lake Street
Virtual Meeting to be held on May 20 hosted by Lake Street.
AEON Biopharma Slides: Corporate presentation
AEON Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
AEON Biopharma Proxy statement: Proxy filing
AEON Biopharma filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AEON Biopharma Proxy statement: Proxy filing
AEON Biopharma filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AEON Biopharma Sets Annual Shareholder Meeting
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a bio...
Aeon receives additional notice related to NYSE American listing standards
AEON Biopharma (AEON) announced that on March 31, 2026, it received a notice from NYSE American indicating that, following its year-end financial results, the Company is not in compliance with…
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimi...
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimi...
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
AEON Biopharma Annual report: Q4 2025
AEON Biopharma has published its Q4 2025 annual report on March 30, 2026.
AEON Biopharma Earnings release: Q4 2025
AEON Biopharma released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Aeon Biopharma announces FDA feedback after Type 2a meeting
Aeon Biopharma (AEON) announced feedback from the FDA following a biosimilar biological product development Type 2a meeting. During the meeting, held in January, the FDA reviewed the company’s propose...
Aeon Biopharma appoints John Bencich as CFO
Aeon Biopharma (AEON) announced the appointment of John Bencich as CFO. Most recently, he served as CEO of Achieve Life Sciences (ACHV).
Aeon Biopharma files to sell 51.29M shares of Class A common stock for holders
16:40 EST Aeon Biopharma (AEON) files to sell 51.29M shares of Class A common stock for holders
AEON Biopharma Registration statement: Registration Filing
AEON Biopharma filed a registration statement on February 9, 2026, providing details about a securities offering with the SEC.
AEON Biopharma Slides: Corporate presentation
AEON Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on January 22, 2026.
Aeon Biopharma reports BPD Type 2a meeting with FDA
Aeon confirmed that it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The company said it looks forward to commenting on the meeting’s substance…
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today vote...
AEON Biopharma Proxy statement: Proxy Filing
AEON Biopharma filed a proxy statement on December 29, 2025, providing details for shareholder voting and corporate governance matters.
AEON Biopharma Proxy statement: Proxy Filing
AEON Biopharma filed a proxy statement on December 19, 2025, providing details for shareholder voting and corporate governance matters.
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercis...
Aeon Biopharma announces rescheduling of BPD Type 2a meeting with FDA
AEON Biopharma (AEON) announced the first closing of its previously announced private placement. Additionally, the Company announced that the U.S. Food and Drug Administration has proposed a new date ...